1. Home
  2. VTRS vs AS Comparison

VTRS vs AS Comparison

Compare VTRS & AS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTRS
  • AS
  • Stock Information
  • Founded
  • VTRS 1961
  • AS 1950
  • Country
  • VTRS United States
  • AS Finland
  • Employees
  • VTRS N/A
  • AS N/A
  • Industry
  • VTRS Medicinal Chemicals and Botanical Products
  • AS
  • Sector
  • VTRS Health Care
  • AS
  • Exchange
  • VTRS Nasdaq
  • AS NYSE
  • Market Cap
  • VTRS 13.0B
  • AS 13.3B
  • IPO Year
  • VTRS N/A
  • AS 2024
  • Fundamental
  • Price
  • VTRS $11.25
  • AS $28.59
  • Analyst Decision
  • VTRS Hold
  • AS Buy
  • Analyst Count
  • VTRS 3
  • AS 14
  • Target Price
  • VTRS $13.67
  • AS $26.07
  • AVG Volume (30 Days)
  • VTRS 9.5M
  • AS 2.8M
  • Earning Date
  • VTRS 02-27-2025
  • AS 02-25-2025
  • Dividend Yield
  • VTRS 4.27%
  • AS N/A
  • EPS Growth
  • VTRS N/A
  • AS N/A
  • EPS
  • VTRS N/A
  • AS N/A
  • Revenue
  • VTRS $15,048,500,000.00
  • AS $4,843,300,000.00
  • Revenue This Year
  • VTRS N/A
  • AS $21.01
  • Revenue Next Year
  • VTRS N/A
  • AS $14.98
  • P/E Ratio
  • VTRS N/A
  • AS N/A
  • Revenue Growth
  • VTRS N/A
  • AS 13.38
  • 52 Week Low
  • VTRS $9.93
  • AS $10.11
  • 52 Week High
  • VTRS $13.62
  • AS $34.00
  • Technical
  • Relative Strength Index (RSI)
  • VTRS 52.72
  • AS 40.74
  • Support Level
  • VTRS $10.74
  • AS $30.30
  • Resistance Level
  • VTRS $11.02
  • AS $31.50
  • Average True Range (ATR)
  • VTRS 0.21
  • AS 1.28
  • MACD
  • VTRS 0.08
  • AS -0.40
  • Stochastic Oscillator
  • VTRS 91.82
  • AS 8.88

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

About AS AMER SPORTS INC

Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $4.4 billion in 2023. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2023, the firm generates 40% of its revenue from the Americas, 33% from Europe, the Middle East, and Africa, 19% from China, and 7% from Asia-Pacific, excluding China.

Share on Social Networks: